Fremanezumab Effective in Reversion of Chronic Migraine to Episodic Migraine

Share this content:
Fremanezumab may revert chronic migraine to episodic migraine in individuals who experience 15 or more headache days per month.
Fremanezumab may revert chronic migraine to episodic migraine in individuals who experience 15 or more headache days per month.
The following article is part of conference coverage from the 2018 American Headache Society Annual Scientific Meeting in San Francisco, California. Neurology Advisor's staff will be reporting breaking news associated with research conducted by leading experts in neurology. Check back for the latest news from AHS 2018.

SAN FRANCISCO — Fremanezumab is an efficacious treatment for migraine prevention, and the same pathophysiologic mechanism targeted by the drug may be clinically effective in the reversion of chronic migraine to episodic migraine. This research was presented at the American Headache Society's 60th Annual Scientific Meeting, held June 27-July 1, 2018, in San Francisco, California.

Based on data from recent studies, researchers suggest that chronic and episodic migraines may be distinct entities. This phase 3, multicenter, double-blind study sought to explore the effect of fremanezumab on the potential reversion from chronic migraine to episodic migraine.

A study population of 1130 subjects with confirmed chronic migraine were randomly assigned to quarterly injections of fremanezumab (n=376), monthly injections of fremanezumab (n=379), or placebo (n=375).

Results showed that more subjects receiving either monthly (n=133) or quarterly (n=121) fremanezumab treatments reverted from chronic migraines to episodic migraines than subjecs receiving placebo (n=86).

At baseline, study participants experienced an average of 18-19 headache days per month. After receiving fremanezumab treatment for 3 months, headache days were significantly reduced to 6-9 days a month.

Study researchers indicate that fremanezumab treatment may be beneficial in reverting chronic migraine to episodic migraine in individuals who experience 15 or more headache days per month and should be considered in the clinical management of migraine headache.

For more coverage of AHS 2018, click here.

Reference

Easo-Joseph S, Halker Singh RB, Cohen JM, et al. Reversion of patients with chronic migraine to an episodic migraine classification with fremanezumab treatment. Presented at: 2018 American Headache Society Annual Scientific Meeting. June 28-July 1, 2018; San Francisco, CA. Abstract 448970.

You must be a registered member of Neurology Advisor to post a comment.

Upcoming Meetings

Sign Up for Free e-newsletters